Dr. Fauci believes COVID-19 might never go away, and Moderna hints a potential trial delay. The two outlooks come as the S&P 500 underperforms.
Overvaluation risks haven’t stopped Nasdaq-listed tech stocks from surging to record highs. The index is up 62% from its March bottom.
Pharmaceutical companies are leading the race to develop a vaccine for Covid-19. Although not all will cross the finish line, some will.
After hitting a market cap of more than $30 billion, Moderna’s share price has come crumbling back to earth.
Moderna has been on a tear since the start of the year. It’s about to end in tears as the stock is trading at insanely high levels.
Improving economic fundamentals, vaccine research progress, and the possibility of additional stimulus will likely boost the S&P 500 Index.
Despite the strong recovery in stocks since the March bottom, analysts fear that valuations are entering a “fairy tale” realm.
The U.S. stock market is soaring due to Moderna’s optimistic vaccine tests. But prominent chartist Larry Williams sees a short-lived rally.
May was a big month for insider selling, suggesting that those in the C-suite are preparing for an upcoming stock market correction.
Positive news of a possible coronavirus vaccine being developed by Moderna was greeted favorably by investors. But was the jubilation warranted?
The Dow Jones went on a 911-point rampage on Monday. But this is the worst kind of stock market rally, and that should scare you.
Moderna will be in a position to produce 1 billion doses of a coronavirus vaccine if one particular candidate passes clinical trials.
The race to develop a coronavirus vaccine is on. Moderna and Inovio stocks have consequently surged. Will investing in these stocks pay off? I wouldn’t put my money on it.
© 2020 Copyright: Hawkfish AS. HQ: Drengsrudhagen 6, 1385, Asker, Norway. Regional Offices: 440 Moy Ave, N9A 2N4, Windsor, Canada. C – 502, Flushing Meadows, Ferns City Road, Doddanekundi, 560037, Bangalore, India. Hurt, 560037, USA.
Editorial Team
Chief Editor: Samburaj Das – samburaj@ccn.com
U.S. Editor: Aaron Weaver – aaron.weaver@ccn.com
Financial Editor: Sam Bourgi – sam.bourgi@ccn.com
Director and Founder: Jonas Borchgrevink -jonas.borchgrevink@ccn.com
HR and Recruiting: Pamela Meropiali – pamela.meropiali@ccn.com
Sales Manager: Pankaj Upadhyay – pankaj@ccn.com.
Phone number: +47 98 48 24 99.